[Des-Arg9]-Bradykinin is a Bradykinin (B1) receptor agonist that displays selectivity for B1 over B2 receptors.
CAT No: R1119
CAS No:15958-92-6
Synonyms/Alias:[Des-Arg9]-BRADYKININ;15958-92-6;9-De-arg-bradykinin;Des-arg(9)-bradykinin;9-Des-arg-BK;(Des-Arg9)-Bradykinin;9-de-L-Argininebradykinin;1-8-Bradykinin;Bradykinin[1-8];58QE2VVE3Q;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid;Bradykinin(1-8);MFCD00236892;Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe;Bradykinin, des-arg(9);[des-Arg(9)]-bradykinin;Bradykinin, des-arg(9)-;Bradykinin, des-arginine(9)-;RPPGFSPF;(Des-Arg9)-Bradykinin acetate salt;desArg9-BK;DABK;1-Des-arg-bradykinin;Des-arg(1) bradykinin;Bradykinin, des-arg(1)-;UNII-58QE2VVE3Q;DES-ARG9 BRADYKININ;l-arginyl-l-prolyl-l-prolylglycyl-l-phenylalanyl-l-seryl-l-prolyl-l-phenylalanine;Bradykinin, de-arginine(1)-;Bradykinin, 1-de-L-arginine-;CHEMBL1890370;CHEBI:133068;VCEHWDBVPZFHAG-POFDKVPJSA-N;HY-P0298;Bradykinin 1-8 acetate salt hydrate;AKOS024457375;NCGC00167250-01;DA-69137;G77854;L-Arg-L-Pro-L-Pro-Gly-L-Phe-L-Ser-L-Pro-L-Phe;(Des-Arg9)-Bradykinin acetate (H-L-Arg-L-Pro-L-Pro-Gly-L-Phe-L-Ser-L-Pro-L-Phe-OH);(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-(2-{[(2S)-1-[(2S)-1-[(2S)-2-AMINO-5-CARBAMIMIDAMIDOPENTANOYL]PYRROLIDINE-2-CARBONYL]PYRROLIDIN-2-YL]FORMAMIDO}ACETAMIDO)-3-PHENYLPROPANAMIDO]-3-HYDROXYPROPANOYL]PYRROLIDIN-2-YL]FORMAMIDO}-3-PHENYLPROPANOIC ACID;(S)-2-((S)-1-((S)-2-((S)-2-(2-((S)-1-((S)-1-((S)-2-amino-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanoic acid;ALANINE, N-(1-(N-(N-(N-(1-(1-L-ARGINYL-L-PROLYL)-L-PROLYL)GLYCYL)-3-PHENYL-L-ALANYL)-L-SERYL)-L-PROLYL)-3-PHENYL-;
[Des-Arg9]-Bradykinin is a synthetic peptide analog derived from the naturally occurring nonapeptide bradykinin, with the C-terminal arginine residue removed. This modification imparts distinct biochemical properties, notably altering its receptor selectivity and functional profile compared to the parent molecule. As a result, [Des-Arg9]-Bradykinin is recognized as a selective agonist for the bradykinin B1 receptor, distinguishing it from bradykinin, which primarily targets the B2 receptor. The compound holds significant research value in the study of kinin-mediated signaling pathways, inflammation, vascular biology, and receptor pharmacology, making it a vital tool for dissecting the roles of bradykinin receptor subtypes in physiological and pathophysiological contexts.
Receptor pharmacology: In the field of receptor biology, [Des-Arg9]-Bradykinin serves as a highly specific probe for the bradykinin B1 receptor. Researchers utilize it to differentiate between B1 and B2 receptor-mediated responses in cellular and tissue assays. Its selective agonism enables detailed characterization of B1 receptor expression, distribution, and functional coupling in various experimental models, including cultured cells, isolated tissues, and recombinant receptor systems. This precise targeting is essential for elucidating the molecular mechanisms underlying kinin receptor activation and for validating receptor subtype-specific pharmacological interventions.
Inflammation and pain research: The compound plays a pivotal role in studies investigating the mechanisms of inflammation, hyperalgesia, and tissue injury. Because the B1 receptor is typically upregulated in response to tissue damage, infection, or chronic inflammatory conditions, [Des-Arg9]-Bradykinin is frequently employed to mimic endogenous B1 receptor activation in experimental models. This application facilitates the exploration of signaling pathways involved in leukocyte recruitment, cytokine production, and nociceptive sensitization, thereby advancing understanding of the molecular basis of inflammatory pain and the development of potential anti-inflammatory strategies.
Vascular biology: [Des-Arg9]-Bradykinin is widely used to investigate the role of B1 receptor activation in vascular tone regulation, endothelial function, and microcirculatory dynamics. By selectively stimulating B1 receptors, researchers can assess their contributions to vasodilation, vascular permeability, and endothelial signaling distinct from B2-mediated effects. These studies are critical for unraveling the complex interplay between kinins and the vascular system, particularly in the context of pathological states such as sepsis, ischemia-reperfusion injury, and chronic vascular inflammation.
Signal transduction studies: The compound is instrumental in dissecting intracellular signaling cascades downstream of B1 receptor activation. Its use in biochemical assays enables the mapping of G-protein-coupled receptor (GPCR) pathways, including the activation of phospholipase C, intracellular calcium mobilization, and MAP kinase signaling. Such studies provide insight into the temporal and spatial dynamics of signal propagation following B1 receptor engagement, supporting the identification of novel regulatory nodes and potential drug targets within kinin-mediated signaling networks.
Peptide-receptor interaction analysis: [Des-Arg9]-Bradykinin is frequently utilized in structure-activity relationship (SAR) studies aimed at understanding the molecular determinants of peptide-receptor binding and activation. Through systematic substitution and modification experiments, researchers employ this peptide as a reference ligand to evaluate how changes in peptide sequence influence receptor affinity, selectivity, and downstream signaling efficacy. These investigations contribute to the rational design of new peptide-based modulators and antagonists targeting the kinin receptor system for research and development purposes.
2. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
3. Emu oil in combination with other active ingredients for treating skin imperfections
5. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More